BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2.
Journal Information
Full Title: Ann Hematol
Abbreviation: Ann Hematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Conflict of interestThe authors declare no competing interests. Conflict of interest The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding Open access funding provided by University of Zürich. TZ received honoraria from Innate, Roche, Novartis, Gilead, Janssen, AstraZeneca, Takeda, Abbvie, and Incyte. TZ is supported by the Hairy Cell Leukemia Foundation and the LLS. WR received honoraria from AstraZeneca; travel support from Amgen, Janssen, and AstraZeneca; and grant from Novartis."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025